279 related articles for article (PubMed ID: 27816512)
41. Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure.
Piper SE; Sherwood RA; Amin-Youssef GF; Shah AM; McDonagh TA
Int J Cardiol; 2015 Jan; 178():284-91. PubMed ID: 25465308
[TBL] [Abstract][Full Text] [Related]
42. Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure.
Kuster N; Huet F; Dupuy AM; Akodad M; Battistella P; Agullo A; Leclercq F; Kalmanovich E; Meilhac A; Aguilhon S; Cristol JP; Roubille F
ESC Heart Fail; 2020 Oct; 7(5):2230-2239. PubMed ID: 32649062
[TBL] [Abstract][Full Text] [Related]
43. The Prognostic Value of Soluble ST2 in Maintenance Hemodialysis Patients: A Meta-Analysis.
Wang S; Wei F; Chen H; Wang Z; Zhang R; Jiang A
Blood Purif; 2020; 49(1-2):114-120. PubMed ID: 31830751
[TBL] [Abstract][Full Text] [Related]
44. Biologic Variability of Soluble ST2 in Patients With Stable Chronic Heart Failure and Implications for Monitoring.
Piper S; deCourcey J; Sherwood R; Amin-Youssef G; McDonagh T
Am J Cardiol; 2016 Jul; 118(1):95-8. PubMed ID: 27189812
[TBL] [Abstract][Full Text] [Related]
45. IL1RL1 single nucleotide polymorphism predicts sST2 level and mortality in coronary and peripheral artery disease.
Lin JF; Wu S; Juang JJ; Chiang FT; Hsu LA; Teng MS; Cheng ST; Huang HL; Sun YC; Liu PY; Ko YL
Atherosclerosis; 2017 Feb; 257():71-77. PubMed ID: 28110258
[TBL] [Abstract][Full Text] [Related]
46. Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery.
Patel DM; Thiessen-Philbrook H; Brown JR; McArthur E; Moledina DG; Mansour SG; Shlipak MG; Koyner JL; Kavsak P; Whitlock RP; Everett AD; Malenka DJ; Garg AX; Coca SG; Parikh CR
Am Heart J; 2020 Feb; 220():253-263. PubMed ID: 31911262
[TBL] [Abstract][Full Text] [Related]
47. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology.
Broch K; Ueland T; Nymo SH; Kjekshus J; Hulthe J; Muntendam P; McMurray JJ; Wikstrand J; Cleland JG; Aukrust P; Gullestad L
Eur J Heart Fail; 2012 Mar; 14(3):268-77. PubMed ID: 22302661
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of soluble ST2 in adults with congenital heart disease.
Geenen LW; Baggen VJM; van den Bosch AE; Eindhoven JA; Cuypers JAAE; Witsenburg M; Boersma E; Roos-Hesselink JW
Heart; 2019 Jul; 105(13):999-1006. PubMed ID: 30700520
[TBL] [Abstract][Full Text] [Related]
49. sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation.
Vílchez JA; Pérez-Cuellar M; Marín F; Gallego P; Manzano-Fernández S; Valdés M; Vicente V; Noguera-Velasco JA; Lip GY; Ordóñez-Llanos J; Roldán V
Eur J Clin Invest; 2015 Sep; 45(9):899-905. PubMed ID: 26081996
[TBL] [Abstract][Full Text] [Related]
50. Soluble ST2 in Patients with Nonvalvular Atrial Fibrillation and Prediction of Heart Failure.
Chen C; Qu X; Gao Z; Zheng G; Wang Y; Chen X; Li H; Huang W; Zhou H
Int Heart J; 2018 Jan; 59(1):58-63. PubMed ID: 29279523
[TBL] [Abstract][Full Text] [Related]
51. Association of soluble ST2 with functional capacity in outpatients with heart failure.
Yucel O; Gul I; Zararsiz A; Demirpence O; Yucel H; Cinar Z; Zorlu A; Yilmaz MB
Herz; 2018 Aug; 43(5):455-460. PubMed ID: 28653113
[TBL] [Abstract][Full Text] [Related]
52. Elevated soluble ST2 concentration may involve in the progression of atrial fibrillation.
Ma X; Yuan H; Luan HX; Shi YL; Zeng XL; Wang Y
Clin Chim Acta; 2018 May; 480():138-142. PubMed ID: 29428199
[TBL] [Abstract][Full Text] [Related]
53. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel.
Januzzi JL; Pascual-Figal D; Daniels LB
Am J Cardiol; 2015 Apr; 115(7 Suppl):70B-5B. PubMed ID: 25670638
[TBL] [Abstract][Full Text] [Related]
54. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP.
Yu J; Oh PC; Kim M; Moon J; Park YM; Lee K; Suh SY; Han SH; Byun K; Ahn T; Kang WC
PLoS One; 2017; 12(8):e0182829. PubMed ID: 28796845
[TBL] [Abstract][Full Text] [Related]
55. Soluble ST2 protein in the short-term prognosis after hospitalisation in chronic systolic heart failure.
Wojtczak-Soska K; Sakowicz A; Pietrucha T; Lelonek M
Kardiol Pol; 2014; 72(8):725-34. PubMed ID: 24846354
[TBL] [Abstract][Full Text] [Related]
56. Role of Soluble ST2 as a Prognostic Marker in Patients with Acute Heart Failure and Renal Insufficiency.
Kim MS; Jeong TD; Han SB; Min WK; Kim JJ
J Korean Med Sci; 2015 May; 30(5):569-75. PubMed ID: 25931787
[TBL] [Abstract][Full Text] [Related]
57. Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure.
Billebeau G; Vodovar N; Sadoune M; Launay JM; Beauvais F; Cohen-Solal A
Eur J Prev Cardiol; 2017 Jul; 24(11):1127-1135. PubMed ID: 28452560
[TBL] [Abstract][Full Text] [Related]
58. Soluble ST2, a biomarker of fibrosis, is associated with multiple risk factors, chronic diseases and total mortality in the OPERA study.
Filali Y; Kesäniemi YA; Ukkola O
Scand J Clin Lab Invest; 2021 Jul; 81(4):324-331. PubMed ID: 33794701
[TBL] [Abstract][Full Text] [Related]
59. The inflammatory markers sST2, HSP27 and hsCRP as a prognostic biomarker panel in chronic heart failure patients.
Traxler D; Zimmermann M; Simader E; Veraar CM; Moser B; Mueller T; Mildner M; Dannenberg V; Lainscak M; Jug B; Ankersmit HJ
Clin Chim Acta; 2020 Nov; 510():507-514. PubMed ID: 32735982
[TBL] [Abstract][Full Text] [Related]
60. Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and meta-analysis.
Sun Y; Pavey H; Wilkinson I; Fisk M
PLoS One; 2021; 16(11):e0259026. PubMed ID: 34723980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
